tbuckley/cabot-search huggingface dataset:
Comparison of Group Medical Visits Combined With Intensive Weight Management vs Group Medical Visits Alone for Glycemia in Patients With Type 2 Diabetes
Authors: William S. Yancy, Matthew J. Crowley, Moahad S. Dar, Cynthia J. Coffman, Amy S. Jeffreys, Matthew L. Maciejewski, Corrine I. Voils, Anna Barton Bradley, David Edelman
Journal: JAMA Internal Medicine (2019)

Traditionally, group medical visits (GMVs) for persons with diabetes improved glycemia by intensifying medications, which infrequently led to weight loss. Incorporating GMVs with intensive dietary change could enable weight loss and improve glycemia while decreasing medication intensity.To examine whether a program of GMVs combined with intensive weight management (WM) is noninferior to GMVs alone for change in glycated hemoglobin (HbA1c) level at 48 weeks (prespecified margin of 0.5%) and superior to GMVs alone for hypoglycemic events, diabetes medication intensity, and weight loss.This randomized clinical trial identified via the electronic medical record 2814 outpatients with type 2 diabetes, uncontrolled HbA1c, and body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 27 or higher from Veterans Affairs Medical Center clinics in Durham and Greenville, North Carolina. Between January 12, 2015, and May 30, 2017, 263 outpatients started the intervention.Participants randomized to the GMV group (n = 136) received counseling about diabetes-related topics with medication optimization every 4 weeks for 16 weeks, then every 8 weeks (9 visits). Participants randomized to the WM/GMV group (n = 127) received low-carbohydrate diet counseling with baseline medication reduction and subsequent medication optimization every 2 weeks for 16 weeks followed by an abbreviated GMV intervention every 8 weeks (13 visits).Outcomes included HbA1c level, hypoglycemic events, diabetes medication effect score, and weight at 48 weeks analyzed using hierarchical generalized mixed models to account for clustering within group sessions.Among 263 participants (mean [SD] age, 60.7 [8.2] years; 235 [89.4%] men; 143 [54.4%] black), baseline HbA1c level was 9.1% (1.3%) and BMI was 35.3 (5.1). At 48 weeks, HbA1c level was improved in both study arms (8.2% in the WM/GMV arm and 8.3% in the GMV arm; mean difference, -0.1%; 95% CI, -0.5% to 0.2%; upper 95% CI, <0.5% threshold; P = .44). The WM/GMV arm had lower diabetes medication use (mean difference in medication effect score, -0.5; 95% CI, -0.6 to -0.3; P < .001) and greater weight loss (mean difference, -3.7 kg; 95% CI, -5.5 to -1.9 kg; P < .001) than did the GMV arm at 48 weeks and approximately 50% fewer hypoglycemic events (incidence rate ratio, 0.49; 95% CI, 0.27 to 0.71; P < .001) during the 48-week period.In GMVs for diabetes, addition of WM using a low-carbohydrate diet was noninferior for lowering HbA1c levels compared with conventional medication management and showed advantages in other clinically important outcomes.ClinicalTrials.gov identifier: NCT01973972.
Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
Authors: Kotoko Yamatani, Tomohiko Ai, Kaori Saito, Haeun Yang, Koya Suzuki, Atsushi Hori, Yuko Murakami-Tonami, Weiguo Zhang, Bing Z Carter, Sonoko Kinjo, Kazuho Ikeo, Katayama Kazuhiro, Hironori Harada, Takashi Miida, Neil P. Shah, Marina Y Konopleva, Yoshihide Hayashizaki, Michael Andreeff, Yoko Tabe
Journal: Blood (2019)
Bilirubin metabolism in the fetus
Authors: Ralph B. Bernstein, Miles J. Novy, George J. Piasecki, Roger Lester, Benjamin T. Jackson
Journal: Journal of Clinical Investigation (1969)

Bilirubin metabolism was studied in dog and monkey fetuses. Bilirubin-(3)H was administered to fetal animals in utero by prolonged intravenous infusion. Fetal plasma disappearance, hepatic uptake, biliary excretion, and placental transfer of bilirubin-(3)H were measured.Bilirubin metabolism and excretion in the fetus was much less efficient than in the adult. Fetal plasma levels of tritium were elevated for prolonged periods, and the combined rate of placental and fetal hepatic excretion was lower than normal values for adult hepatic excretion. Species differences were noted. Hepatic conjugation and excretion appeared to be the primary mechanism of fetal metabolism in the dog. In contrast, the amounts of conjugated bilirubin-(3)H excreted in fetal monkey bile were negligible. Small amounts of (3)H-labeled bilirubin derivatives were excreted in fetal bile, but 10 times as much of the administered material was transferred intact across the placenta and excreted by the maternal liver. The relationship of this functional difference to known anatomic and biochemical species differences is discussed. Preliminary observations on alternate routes of fetal bilirubin metabolism were obtained.
Siklooksijenaz-2 Enzim İnhibitörleri ve Aspirin Dahil Nonsteroid Anti İnflamatuvar Ajanların Kullanımı Üzerine Konsensus Geliştirme Konferansı
Authors: C. Mel Wilcox, Jeroan Allison, Keith Benzuly, Marie Borum, Byron Cryer, Tilo Grosser, Richard Hunt, Uri Ladabaum, Angel Lanas, Harold Paulus, Carol Regueiro, Robert S. Sandler, sup> ve Lee Simon ##<
Journal: Clinical Gastroenterology and Hepatology (2006)
Trends in the Use of Administrative Codes for Physical Abuse Hospitalizations
Authors: Henry T. Puls, James D. Anderst, Amber Davidson, Matthew Hall
Journal: JAMA Pediatrics (2019)

trafficking 5 and the greater awareness and sensitivity of medical professionals regarding sexual assault.The increased rates of sexual abuse cases observed in this study are coupled with an ongoing concern about the quality of care and the treatment of sexually abused children who are admitted to EDs, which may not consistently adhere to the recommendations for care endorsed by the American Academy of Pediatrics and the Centers for Disease Control and Prevention. 6 One limitation of this study was that the data did not provide information regarding the situational nature of sexual abuse; thus, we could not identify a clear association between ED admissions for sexual abuse and multiple risk factors.Despite this and other limitations, the study provides a unique epidemiologic surveillance contribution regarding the patterns and characteristics of child sexual abuse in the United States.
TMIC-36. ALDH1A2 AS A NOVEL PUTATIVE MARKER OF MACROPHAGE DIFFERENTIATION IN GBM
Authors: Stephanie Sanders, Denise Herpai, Lance Miller, Waldemar Debinski
Journal: Neuro-Oncology (2019)

Abstract Tumor-associated macrophages (TAM) are abundant in glioblastoma (GBM), composing up to 30% of the total tumor mass. However, their genotype/phenotype and exact role in tumor progression and immune suppression are not fully understood. Macrophages are believed to be polarized along a spectrum spanning from M0, M1, and M2 states. M1 TAMs are proinflammatory while M2 TAMs are associated with anti-inflammatory, pro-tumor responses. For example, using gelatin zymography we saw an increase in MMP 2 and 9 activities in co-culture of GBM cells and M2 polarized macrophages. In search for factors determining M2 type TAMs, we found Aldehyde Dehydrogenase 1 family A2 (ALDH1A2) to be highly over-expressed in M2 polarized THP1 cells using a gene expression array. We also performed single cell sequencing on CD45+ cells isolated from GBM tumors using antibody-conjugated magnetic beads. Monocytic/macrophage cells were found in 2 clusters and ALDH1A2 expression was increased in 2.1% of CD68+/CD163+ cells in Cluster 1 and 2.7% of CD68+/CD163+ cells in Cluster 2. Notably, ALDH1A2 was not detected in peripheral blood mononuclear cells. Analysis of the single cell sequencing data has led to identification of several genes whose expression is increased in ALDH1A2+ cells compared to ALDH1A2- cells. These genes are associated with lipid metabolism, regulation of neoplastic transformation, and insulin growth factor signaling. To further validate these results, we co-stained GBM tumor sections for CD163 and ALDH1A2 and observed that ALDH1A2 is co-localized in M2 macrophages. We have noticed a propensity of ALDH1A2+ cells to be associated with tumor neovasculature. Being that ALDH1A2 is the main enzyme in retinoic acid (RA) synthesis, it is plausible that this could represent another possible function of these enzyme-positive TAMs. Taken together these data suggest a role for ALDH1A2 as a novel putative marker of a subset of M2 TAM phenotype and function in GBM.
Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above
Authors: Christopher A. Yasenchak, Rodolfo Bordoni, Victor Yazbeck, Dipti Patel-Donnelly, Timothy Larson, Trevor Newhook, Linda Ho, Matthew Mei
Journal: Blood (2019)
Requests for Diagnoses of Sexually Transmitted Diseases on a Social Media Platform
Authors: Alicia L. Nobles, Eric C. Leas, Benjamin M. Althouse, Mark Dredze, Christopher A. Longhurst, Davey M. Smith, John W. Ayers
Journal: JAMA (2019)

This study monitored online posts from readers seeking specific health information on a social media platform to evaluate the volume of information requests, whether readers sought an initial or second opinion for diagnosis, and the amount of response time before a reply answer was sent.
Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes
Authors: Abhishek A Mangaonkar, Alejandro Ferrer, Filippo Pinto E Vairo, Margot Cousin, Ryan Kuisle, Cassie C Kennedy, Giacomo Coltro, Naseema Gangat, William J Hogan, Mark Litzow, Steve Peters, Eric W. Klee, JP Scott, James P Utz, Misbah Baqir, Eva Carmona Porquera, Hiroshi Sekiguchi, Shakila P Khan, Vilmarie Rodriguez, Douglas A Simonetto, Patrick S Kamath, Avni Y Joshi, Mark E Wylam, Mrinal M Patnaik
Journal: Blood (2019)
T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.
Authors: Eva Rossmann, Parviz Kokhaei, Fariba Mozaffari, Marzia Palma, Anders Osterborg, Hakan Mellstedt, A. Raja Choudhury
Journal: Blood (2008)
Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons
Authors: Ausenda Machado, Clara Mazagatos, Frederika Dijkstra, Irina Kislaya, Alin Gherasim, Scott A McDonald, Esther Kissling, Marta Valenciano, Adam Meijer, Mariëtte Hooiveld, Baltazar Nunes, Amparo Larrauri
Journal: Eurosurveillance (2019)

BackgroundTo increase the acceptability of influenza vaccine, it is important to quantify the overall benefits of the vaccination programme.AimTo assess the impact of influenza vaccination in Portugal, Spain and the Netherlands, we estimated the number of medically attended influenza-confirmed cases (MAICC) in primary care averted in the seasons 2015/16 to 2017/18 among those ≥ 65 years.MethodsWe used an ecological approach to estimate vaccination impact. We compared the number of observed MAICC (n) to the estimated number that would have occurred without the vaccination programme (N). To estimate N, we used: (i) MAICC estimated from influenza surveillance systems, (ii) vaccine coverage, (iii) pooled (sub)type-specific influenza vaccine effectiveness estimates for seasons 2015/16 to 2017/18, weighted by the proportion of virus circulation in each season and country. We estimated the number of MAICC averted (NAE) and the prevented fraction (PF) by the vaccination programme.ResultsThe annual average of NAE in the population ≥ 65 years was 33, 58 and 204 MAICC per 100,000 in Portugal, Spain and the Netherlands, respectively. On average, influenza vaccination prevented 10.7%, 10.9% and 14.2% of potential influenza MAICC each season in these countries. The lowest PF was in 2016/17 (4.9-6.1%) with an NAE ranging from 24 to 69 per 100,000.ConclusionsOur results suggest that influenza vaccination programmes reduced a substantial number of MAICC. Together with studies on hospitalisations and deaths averted by influenza vaccination programmes, this will contribute to the evaluation of the impact of vaccination strategies and strengthen public health communication.
Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis
Authors: Paolo Milani, Francesca Fazio, Marco Basset, Tamara Berno, Alessandra Larocca, Andrea Foli, Marcello Riva, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, Maria Teresa Petrucci, Giampaolo Merlini, Giovanni Palladini
Journal: Blood (2019)
Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy
Authors: Jonathan E. Kolitz, Daniel H. Ryan, Laura F. Newell, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Gary J. Schiller, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes
Journal: Blood (2019)
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus
Authors: Steven Fishbane, Aamir Jamal, Catherine Munera, Warren Wen, Frédérique Menzaghi
Journal: New England Journal of Medicine (2019)

Difelikefalin is a peripherally restricted and selective agonist of kappa opioid receptors that are considered to be important in modulating pruritus in conditions such as chronic kidney disease.In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients undergoing hemodialysis who had moderate-to-severe pruritus to receive either intravenous difelikefalin (at a dose of 0.5 μg per kilogram of body weight) or placebo three times per week for 12 weeks. The primary outcome was the percentage of patients with an improvement (decrease) of at least 3 points from baseline at week 12 in the weekly mean score on the 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS; scores range from 0 to 10, with higher scores indicating greater itch intensity). The secondary outcomes included the change from baseline in itch-related quality-of-life measures, the percentage of patients with an improvement of at least 4 points in the WI-NRS score at week 12, and safety.A total of 378 patients underwent randomization. A total of 82 of 158 patients (51.9%) in the difelikefalin group had a decrease of at least 3 points in the WI-NRS score (primary outcome), as compared with 51 of 165 (30.9%) in the placebo group. The imputed percentage of patients with a decrease of at least 3 points in the WI-NRS score was 49.1% in the difelikefalin group, as compared with 27.9% in the placebo group (P<0.001). Difelikefalin also resulted in a significant improvement from baseline to week 12 in itch-related quality of life as measured by the 5-D itch scale and the Skindex-10 scale. The imputed percentage of patients with a decrease of at least 4 points in the WI-NRS score at week 12 was significantly greater in the difelikefalin group than in the placebo group (37.1% [observed data: 64 of 158 patients] vs. 17.9% [observed data: 35 of 165 patients], P<0.001). Diarrhea, dizziness, and vomiting were more common in the difelikefalin group than in the placebo group.Patients treated with difelikefalin had a significant reduction in itch intensity and improved itch-related quality of life as compared with those who received placebo. (Funded by Cara Therapeutics; KALM-1 ClinicalTrials.gov number, NCT03422653.).
Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies
Authors: May Daher, Rafet Basar, Elif Gokdemir, Natalia Baran, Nadima Uprety, Mayela Carolina Mendt, Lucila Kerbauy, Mayra Shanley, Ana Karen Nunez Cortes, Li Li, Pinaki P Banerjee, Vakul Mohanty, Junjun Lu, Gonca Ozcan, Emily Ensley, Vandana Nandivada, Mecit Kaplan, Mustafa H Bdaiwi, Enli Liu, Sonny Ang, Ken Chen, Marina Y Konopleva, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood (2019)
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
Authors: Chad C. Bjorklund, Jian Kang, Michael Amatangelo, Ann Polonskaia, Mark Katz, Hsiling Chiu, Suzana Couto, Maria Wang, Yan Ren, Maria Ortiz, Fadi Towfic, J. Erin Flynt, William Pierceall, Anjan Thakurta
Journal: Leukemia (2019)
GENE-08. SECONDARY GLIOBLASTOMA, IDH-WILDTYPE ARISING IN DIFFUSE ASTROCYTOMA, IDH-MUTANT: A CASE REPORT
Authors: Kyu Sang Lee, Gheeyoung Choe
Journal: Neuro-Oncology (2019)

Abstract Primary glioblastoma develops de novo without clinical or histological evidence of a low-grade precursor lesion, while secondary glioblastoma develops from a low-grade glioma. The same IDH mutation is observed in almost secondary glioblastomas that occurs in low-grade gliomas with IDH mutation. Present report is an extraordinary case of secondary glioblastoma, IDH-wildtype arising in diffuse astrocytoma, IDH-mutant. A 31-year-old female presented with seizure 3 months ago, who had a history of operation for diffuse astrocytoma, IDH-mutant on the left frontal lobe 6 years ago. Magnetic resonance imaging test revealed new infiltrative lesions (6.5cm) in left frontal lobe and corpus callosum, in addition to the non-enhancing mass (3.4cm). New infiltrative lesion suspected anaplastic change and the patient underwent tumorectomy. Microscopically, non-enhancing lesion showed high cellularity, moderate nuclear atypia and brisk mitosis. Microvascular proliferation and necrosis were absent that can be diagnosis as anaplastic astrocytoma. However, new infiltrative lesion showed microvascular proliferation and necrosis that acceptable for diagnosis as glioblastoma. IDH-1 immunohistochemistry (IHC) was positive in anaplastic astrocytoma but negative in glioblastoma. In addition, we assessed NGS based on the SNUBH Brain v1.0 (Macrogen, Seoul, South Korea) panel. Similar to IHC result, IDH-1 (p.Arg132His) mutation was found in anaplastic astrocytoma but not in glioblastoma. Interestingly, ATRX (p.Gln1670Ter) and TP53 (p.His193Arg) mutations were found in both lesions. Additionally, PTEN (p.His296Pro) mutation was identified in glioblastoma component only. Until now, it is well-known hypothesis that the IDH mutation initiated in glial progenitor cell and the other genetic mutations occur sequentially in pathogenesis of secondary glioblastoma. Notably, this is the first case report that other genetic alterations can be initiated before IDH mutation contrary to previous hypothesis. In our case, mutation of ATRX and TP53 might be initiated, and PTEN and IDH-1 mutations were sequentially occurred in glioblastoma and anaplastic astrocytoma, respectively.
C3435T Polymorphism of MDR1 Gene Is Not Associated with p-Glycoprotein Function of Leukemic Blasts and Clinical Outcomes in Patients with Acute Myeloid Leukemia.
Authors: Michael Jinpyo Lee, Eun-Hye Hur, Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Miee Seol, Keun-Hee Kim, Hee-Jung Lee, Ip-Sol Kang, Kyung-Soo Shim, Seong-Gil Ryu, Young-Ah Kang, Young-Shin Lee, Chan-Jeoung Park, Hyung-Sook Chi, Kyoo-Hyung Lee
Journal: Blood (2007)
Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN)
Authors: Monika M Kutyna, Amilia Wee, Sharon Paton, Dimitrios Cakouros, Agnes Arthur, Rakchha Chhetri, Deepak Singhal, Stan Gronthos, Devendra K Hiwase
Journal: Blood (2019)
Non-Traditional CD4+ CD25–CD69+ Regulatory T Cells Is Correlated To Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Xiaosu Zhao, Xuhua Wang, Yingjun Chang, Xiangyu Zhao, Xiaohui Zhang, Daihong Liu, Lanping Xu, Kaiyan Liu, Xiaojun Huang
Journal: Blood (2013)
Personalized Cancer Therapy: YES1 Is the New Kid on the Block
Authors: Kunal Rai
Journal: Cancer Research (2019)

Abstract The key bottleneck for the continued success of precision medicine in cancer lies in identifying more targetable genes and associated efficacious clinically usable inhibitors. In this issue of Cancer Research, Hamanaka and colleagues identify YES1 kinase as a targetable cancer target and generate an effective chemical inhibitor for YES1 and demonstrate its efficacy in YES1-amplified tumors. See related article by Hamanaka et al., p. 5734
Carcinoma of the Cervix
Authors: T. Richard Hofmann
Journal: JAMA (1963)

<h3>To the Editor:</h3> —I am intrigued by your statement that carcinoma of the cervix accounts for 75% of all the malignant tumors (<i>JAMA</i>182:674 [Nov 10] 1962). In the September-October, 1961, issue (Vol 11, No 5, p 204) of the Cancer booklet published by the American Cancer Society, Inc., the following table of cancer sites is given for the United States: In the July-August, 1962, issue (Vol 12, No 4, p 122) of the same publication the following statistic appears: Carcinoma of the cervix constitutes 11 per cent of all cancers and 55 to 65 per cent of all cancers of the reproductive system. This applies to cancers of the female reproductive system. It is also a well-established fact that there is a considerable regional variation in the incidence of gynecologic malignancies. On page 155 of the same issue the statement is made that, "Carcinoma of the colon and rectum
PATH-56. PYROSEQUENCING METHOD FOR RAPID DETECTION OF KIAA1549-BRAF FUSION GENES IN PEDIATRIC BRAIN TUMORS
Authors: Yuzaburo Shimizu, Satoshi Adachi, Mario Suzuki, Osamu Akiyama, Ikuko Ogino, Akihide Kondo
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Fusion genes driving tumorigenesis have drawn the attention of oncologists and researchers. Recently, independent genomic researchers have identified a tandem duplication of BRAF at 7q34 that leads to several KIAA1549-BRAF gene exon fusions in the majority of pilocytic astrocytoma (PA). Because KIAA1549-BRAF fusion transcripts are usually absent in diffuse astrocytoma, these genetic alterations may have diagnostic value. Despite the importance of such molecular alterations, there are no comprehensive reproducible methods to detect these fusion genes. METHODS Samples of brain tumors were selected retrospectively from our institution. 22 pediatric brain tumors of five types, namely PA, oligodendroglioma (OD), anaplastic astrocytoma (AA), glioblastoma (GBM) and, ganglioglioma (GG), were evaluated to detect KIAA1549-BRAF fusion genes using a pyrosequencing-based method following RNA isolation, cDNA synthesis and real-time polymerase chain reaction. We designed the primers to detect the three most common fusion variants: KIAA1549 ex15-BRAF ex9, KIAA1549 ex16-BRAF ex9, and KIAA1549 ex16-BRAF ex11. RESULTS Our method successfully detected KIAA1549-BRAF fusion in 16 out of 22 samples, that is, eleven PA, two OD, one AA, one GBM, and one GG. The entire procedure from RNA extraction to obtaining mutation data was performed within 2 hours. CONCLUSION A comprehensive method for detecting fusion genes in pediatric brain tumors was evaluated. This method identified KIAA1549–BRAF fusion variants quickly compared to other methods. Our results will be useful for studies on intraoperative diagnosis and classification of tumors for improving surgical decisions.
Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms
Authors: Ken-Hong Lim, Yu-Cheng Chang, Yi-Hao Chiang, Huan-Chau Lin, Ling Huang, Wei-Ting Wang, Ying-Wen Su, Ming-Chih Chang, Yi-Fang Chang, Caleb Gon-Shen Chen
Journal: Blood (2019)
AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: Eliza A Hawkes, Kate Manos, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong
Journal: Blood (2019)